Bristol Myers Squibb’s deucravacitinib and Ipsen’s palovarotene are among the latest drugs for which the European Medicines Agency is due to adopt an opinion this week on whether or not they should be granted EU-wide marketing approval.
Deucravacitinib is for treating plaque psoriasis, while palovarotene is for the ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), which causes soft tissues to transform permanently into bone
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?